Estrogen modulates serotonin effects on vasoconstriction through Src inhibition

다국어 초록 (Multilingual Abstract)

Estrogen has diverse effects on cardiovascular function, including regulation of the contractile response to vasoactive substances such as serotonin. The serotonin system recently emerged as an important player in the regulation of vascular tone in humans. However, hyperreactivity to serotonin appears to be a critical factor for the pathophysiology of hypertension. In this study, we examined the modulatory mechanisms of estrogen in serotonin-induced vasoconstriction by using a combinatory approach of isometric tension measurements, molecular biology, and patchclamp techniques. 17β-Estradiol (E2) elicited a significant and concentration-dependent relaxation of serotonininduced contraction in deendothelialized aortic strips isolated from male rats. E2 triggered a relaxation of serotonininduced contraction even in the presence of tamoxifen, an estrogen receptor antagonist, suggesting that E2-induced changes are not mediated by estrogen receptor. Patch-clamp studies in rat arterial myocytes showed that E2 prevented Kv channel inhibition induced by serotonin. Serotonin increased Src activation in arterial smooth muscle required for contraction, which was significantly inhibited by E2. The estrogen receptor-independent inhibition of Src by E2 was confirmed in HEK293T cells that do not express estrogen receptor. Taken together, these results suggest that estrogen exerts vasodilatory effects on serotonin-precontracted arteries via Src, implying a critical role for estrogen in the prevention of vascular hyperreactivity to serotonin.

참고문헌 (Reference)

1 Lu, R., "c-Src tyrosine kinase, a critical component for 5-HT2A receptormediated contraction in rat aorta" 586 : 3855-3869, 2008

2 Thompson, L. P., "Vascular responsiveness to serotonin metabolites in mineralocorticoid hypertension" 9 : 277-281, 1987

3 Losordo, D. W., "Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women" 89 : 1501-1510, 1994

4 Doggrell, S. A., "The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation" 12 : 805-823, 2003

5 Menazza, S., "The expanding complexity of estrogen receptor signaling in the cardiovascular system" 118 : 994-1007, 2016

6 Kim, E. S., "Status of women in cardiovascular clinical trials" 29 : 279-283, 2009

7 Reckelhoff, J. F., "Sex and gender differences in cardiovascular-renal physiology and pathophysiology" 75 : 745-746, 2010

8 Cogolludo, A., "Serotonin inhibits voltage-gated K+currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1, and KV1.5channel internalization" 98 : 931-938, 2006

9 Haliloglu, B., "Serotonin dilemma in postmenopausal women: is it low or high?" 60 : 148-152, 2008

10 Bae, Y. M., "Serotonin depolarizes the membrane potential in rat mesenteric artery myocytes by decreasing voltage-gated K+currents" 347 : 468-476, 2006

11 성동준, "Serotonin contracts the rat mesenteric artery by inhibiting 4-aminopyridine-sensitive Kv channels via the 5-HT2A receptor and Src tyrosine kinase" 생화학분자생물학회 45 (45): 1-10, 2013

12 Watts, S. W., "Serotonin and blood pressure regulation" 64 : 359-388, 2012

13 Hulley, S., "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group" 280 : 605-613, 1998

14 Brenner, B., "Plasma serotonin levels and the platelet serotonin transporter" 102 : 206-215, 2007

15 Sasaki, H., "PDE5 inhibitor efficacy is estrogen dependent in female heart disease" 124 : 2464-2471, 2014

16 Webb, R. C., "Oscillatory contractions in vertebral arteries from hypertensive subjects" 12 : 69-77, 1992

17 Mendelsohn, M. E., "Nongenomic, ER-mediated activation of endothelial nitric oxide synthase: how does it work? What does it mean?" 87 : 956-960, 2000

18 Hulley, S., "Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)" 288 : 58-66, 2002

19 Bittner, V., "Menopause, age, and cardiovascular risk: a complex relationship" 54 : 2374-2375, 2009

20 Haines, C. J., "Menopause management: a cardiovascular risk-based approach" 13 : 328-339, 2010

21 Coylewright, M., "Menopause and hypertension:an age-old debate" 51 : 952-959, 2008

22 Haynes, M. P., "Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells" 87 : 677-682, 2000

23 Sudhir, K., "Mechanisms of estrogen-induced vasodilation: in vivo studies in canine coronary conductance and resistance arteries" 26 : 807-814, 1995

24 Simoncini, T., "Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase" 407 : 538-541, 2000

25 Huzoor, A., "Increased vascular contractile sensitivity to serotonin in spontaneously hypertensive rats is linked with increased turnover of phosphoinositide" 45 : 577-583, 1989

26 Lindner, V., "Increased expression of estrogen receptor-beta mRNA in male blood vessels after vascular injury" 83 : 224-229, 1998

27 Venkov, C. D., "Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function" 94 : 727-733, 1996

28 Holm, A., "Identification and characterization of new mechanisms in vascular oestrogen signalling" 113 : 287-293, 2013

29 Cummings, S. A., "Hypersensitivity of mesenteric veins to 5-hydroxytryptamine- and ketanserin-induced reduction of portal pressure in portal hypertensive rats" 89 : 501-513, 1986

30 Karas, R. H., "Human vascular smooth muscle cells contain functional estrogen receptor" 89 : 1943-1950, 1994

31 Schnatz, P. F., "Hormonal therapy: does it increase or decrease cardiovascular risk?" 61 : 673-681, 2006

32 Berdanier, C. D., "Handbook of Nutrition and Food" CRC Press 2007

33 Kim-Schulze, S., "Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells" 94 : 1402-1407, 1996

34 Harman, S. M., "Estrogen replacement in menopausal women: recent and current prospective studies, the WHI and the KEEPS" 3 : 254-269, 2006

35 Gustafsson, J. A., "Estrogen receptor beta--getting in on the action?" 3 : 493-494, 1997

36 Gustafsson, J. A., "Estrogen receptor beta--a new dimension in estrogen mechanism of action" 163 : 379-383, 1999

37 Watanabe, T., "Estrogen receptor beta mediates the inhibitory effect of estradiol on vascular smooth muscle cell proliferation" 59 : 734-744, 2003

38 Chen, Z., "Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen" 103 : 401-406, 1999

39 Manson, J. E., "Estrogen plus progestin and the risk of coronary heart disease" 349 : 523-534, 2003

40 Iafrati, M. D., "Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice" 3 : 545-548, 1997

41 Haiyue Lin, "Enhancement of 5-HT2A receptor function and blockade of Kv1.5 by MK801 and ketamine: implications for PCP derivativeinduced disease models" 생화학분자생물학회 50 : 1-8, 2018

42 Dohi, Y., "Endothelin in hypertensive resistance arteries. Intraluminal Extra. Dysfunct" 18 : 543-549, 1991

43 Karas, R. H., "Effects of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice" 89 : 534-539, 2001

44 Teoh, H., "Differential effects of 17betaestradiol and testosterone on the contractile responses of porcine coronary arteries" 129 : 1301-1308, 2000

45 Register, T. C., "Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta" 64 : 187-191, 1998

46 Rosano, G. M., "Cardiovascular aspects of menopausal hormone replacement therapy" 12 (12): 41-46, 2009

47 Hodis, H. N., "Assessing benefits and risks of hormone therapy in 2008: new evidence, especially with regard to the heart" 75 (75): S3-S12, 2008

48 Moreno, L., "Anatomical differences in responsiveness to vasoconstrictors in the mesenteric veins from normal and portal hypertensive rats" 354 : 474-480, 1996

49 Grodstein, F., "A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease" 133 : 933-941, 2000

50 Katzenellenbogen, B. S., "A new actor in the estrogen receptor drama--enter ER-beta" 138 : 861-862, 1997

51 Watts, S. W., "5-HT in systemic hypertension: foe, friend or fantasy?" 108 : 399-412, 2005